Clinical trials
No Disease or Condition is Being Studied clinical trials
Below are recruiting no disease or condition is being studied clinical trials, each written for real people, not researchers. We’re tracking 18,404 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06405087RecruitingPhase 3
Long-term study of vedolizumab for children with IBD
This study is for children and teenagers with ulcerative colitis or Crohn's disease who have already completed a previous vedolizumab study and are doing well. It will look at the long-term safety and effectiveness of continuing vedolizumab treatment.
Phoenix, ArizonaAges 2–17 - NCT06414967Recruiting
Music therapy for irritability in Huntington's disease
This study tests if music therapy can help reduce irritability and impulsivity in people with Huntington's disease. You'll participate in music sessions to see if it improves your mood and behavior.
PoitiersAges 18 years+ - NCT00267501Recruiting
Study collects data and samples to understand eosinophilic conditions
This study collects information and biological samples to better understand what causes certain allergic/eosinophilic conditions. It may help researchers learn mechanisms and improve future care.
Cincinnati, OhioAges Any age - NCT04280510Recruiting
Study of immune-related gut illnesses in adults
This study looks at adults with immune-related stomach and intestine problems to better understand what may cause them. If you qualify, you can share information and consent to help researchers learn how these conditions work.
CréteilAges 18 years+ - NCT06363760Enrolling by invitation
Long-term follow-up after EDIT-301 gene therapy
This long-term follow-up study monitors people with sickle cell disease or transfusion-dependent beta-thalassemia who have already received the gene-editing therapy EDIT-301. It helps researchers understand how safe and effective the treatment is over time.
Oakland, CaliforniaAges 12–50 - NCT06375993Enrolling by invitationPhase 1
Prula-cel for autoimmune diseases: a phase 1 study
This trial tests a new treatment called prulacabtagene leucel (prula-cel), which is a type of immune cell therapy (CAR T-cells) for people with certain autoimmune diseases. It aims to see if it can reset the immune system and reduce disease activity in conditions like lupus, scleroderma, vasculitis, or myositis.
Redwood City, CaliforniaAges 18–80 - NCT06374498Enrolling by invitation
Looking inside heart arteries to improve stent placement
This study tests a new imaging technique to help doctors see inside your heart arteries during a stent procedure. It may help guide treatment and improve outcomes for people with heart disease.
Boston, MassachusettsAges 18 years+ - NCT04724941Recruiting
Screening for alpha-synuclein in early Parkinson’s risk
This study looks for changes in a protein called alpha-synuclein in people who may be in the early “prodromal” stage before Parkinson’s symptoms fully appear. It may help researchers find early markers and understand who is more likely to develop Parkinson’s disease.
KielAges 50–99 - NCT06339398Recruiting
Exercise dose and brain health in Parkinson's
This study looks at how different amounts of physical exercise affect brain chemicals, movement symptoms, and brain connections in people with Parkinson's disease. You would walk and do exercises while researchers track changes over time.
Cassino, FrosinoneAges 30–80 - NCT06344026Enrolling by invitationPhase 1
A cell therapy trial for Parkinson's disease
This trial tests a new treatment made from your own cells to replace damaged brain cells, aiming to improve movement and reduce symptoms. It's for people who have had Parkinson's for at least 4 years and respond well to levodopa.
Tucson, ArizonaAges 40–75 - NCT06322667Recruiting
Study of lecanemab in early Alzheimer's disease
This study tracks the real-world experience of people with early Alzheimer's disease who are already taking lecanemab. It aims to better understand how the medication works and its safety in everyday medical practice.
HiroshimaAges 18 years+ - NCT05578495Recruiting
Track daily movement to predict future health problems
This study looks at how active versus sedentary you are (often using a digital signature from your daily routine) to see how it relates to developing multiple health conditions over time. It may help researchers understand which activity patterns are linked with higher risk, especially in certain long-term illnesses.
Clermont-FerrandAges 18–90 - NCT06318533RecruitingEarly Phase 1
Engineered immune cell therapy for autoimmune diseases
This early-stage study tests an experimental treatment that uses engineered immune cells (called CAR natural killer cells) to calm overactive immune responses in people with moderate to severe autoimmune diseases that have not fully responded to standard treatments. It aims to offer a new option for patients who have not gotten enough benefit from usual therapies.
Zhenjiang, JiangsuAges 18–70 - NCT06297096RecruitingPhase 3
Testing a two-drug combo for lung scarring in scleroderma
This study tests whether a combination of two drugs, nintedanib and tocilizumab, can help people with systemic sclerosis (a condition that causes skin and organ hardening) who also have lung scarring (interstitial lung disease). The goal is to find a treatment that can slow down the disease.
Warsaw, Masovian VoivodeshipAges 18–74 - NCT06297590RecruitingPhase 1
First human study of a new Alzheimer's drug
This study tests an experimental drug (LY3954068) for people with early Alzheimer's disease. It aims to see if the drug is safe and may slow memory loss. You'll need a PET scan to measure tau protein in the brain and have a study partner who can help attend appointments.
Maitland, FloridaAges 50–85 - NCT06295614Recruiting
ARC-IM therapy for walking problems in Parkinson's
This study tests a new therapy called ARC-IM to help with walking issues like freezing or balance problems in people with Parkinson's. It aims to see if the therapy is safe and can improve movement.
Lausanne, Canton of VaudAges 18 years+ - NCT06296472Recruiting
Comparing hand therapy for De Quervain's disease after steroid injection
This trial compares two types of hand therapy for patients with De Quervain's disease, a painful condition affecting the thumb tendons. One group receives standard hand therapy, while the other gets a new approach after an ultrasound-guided steroid injection.
BolognaAges 18 years+ - NCT06294613Recruiting
Robotic eye surgery for vitreoretinal conditions
This study tests a robotic system to assist eye surgery for certain retina and vitreous conditions, such as bleeding in the eye or a wrinkle on the macula. It aims to see if the robot can safely help improve vision.
Ghent, East FlandersAges 18–85 - NCT06283966RecruitingPhase 3
Triple inhaler for COPD with heart risk
This study tests a triple-combination inhaler (budesonide, glycopyrronium, and formoterol) to see if it can help protect the heart and lungs in people with COPD who also have heart problems or high risk for them.
Athens, AlabamaAges 40–80 - NCT06270316RecruitingPhase 1/Phase 2
Gene therapy for classic Fabry disease
This trial tests a one-time gene therapy called AMT-191 for men with classic Fabry disease who are still having symptoms despite enzyme replacement therapy. The goal is to see if it can reduce pain and stomach problems and improve overall health.
Birmingham, AlabamaAges 18–65 - NCT06233461RecruitingPhase 2
A study of TAK-279 for Crohn's disease
This study tests an oral medication called TAK-279 to see if it can safely reduce inflammation in the bowel for people with moderate to severe Crohn's disease who haven't had success with other treatments.
Murrieta, CaliforniaAges 18–75 - NCT06227910RecruitingPhase 3
Study of vedolizumab with or without upadacitinib for Crohn's disease
This trial tests combining two medicines, vedolizumab and upadacitinib, to see if they work better together than vedolizumab alone for people with moderate to severe Crohn's disease that hasn't responded well to other treatments.
La Jolla, CaliforniaAges 18–65 - NCT06189963RecruitingPhase 1/Phase 2
Cell therapy trial for moderate Alzheimer's disease
This trial tests a new immune cell therapy (SNK01) for people with moderate Alzheimer's disease. The goal is to see if it can slow down memory and thinking decline.
Glendale, CaliforniaAges 40–85 - NCT06194799Enrolling by invitationPhase 3
Long-term ACP-204 for Alzheimer's psychosis
This study tests a long-term medicine (ACP-204) for people with Alzheimer's disease who also have psychosis (hallucinations or delusions). If you took part in the earlier ACP-204 study, this open-label extension lets you continue receiving the medicine to see how well it works over time.
Costa Mesa, CaliforniaAges 55–95
Hear when a new No Disease or Condition is Being Studied trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for no disease or condition is being studied?
- Yes. Clin2 currently lists 18,404 recruiting no disease or condition is being studied studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a no disease or condition is being studied trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a no disease or condition is being studied trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.